These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1290 related articles for article (PubMed ID: 25398489)

  • 41. Development of psoriasis by continuous neutrophil infiltration into the epidermis.
    Katayama H
    Exp Dermatol; 2018 Oct; 27(10):1084-1091. PubMed ID: 30019426
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
    Puig L
    Drugs Today (Barc); 2017 May; 53(5):283-297. PubMed ID: 28650001
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis.
    Carrier Y; Ma HL; Ramon HE; Napierata L; Small C; O'Toole M; Young DA; Fouser LA; Nickerson-Nutter C; Collins M; Dunussi-Joannopoulos K; Medley QG
    J Invest Dermatol; 2011 Dec; 131(12):2428-37. PubMed ID: 21881584
    [TBL] [Abstract][Full Text] [Related]  

  • 44. T cell responses in psoriasis and psoriatic arthritis.
    Diani M; Altomare G; Reali E
    Autoimmun Rev; 2015 Apr; 14(4):286-92. PubMed ID: 25445403
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review.
    Thibodaux RJ; Triche MW; Espinoza LR
    Expert Opin Biol Ther; 2018 Jul; 18(7):821-827. PubMed ID: 29949399
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of psoriasis and psoriatic arthritis.
    Papoutsaki M; Costanzo A
    BioDrugs; 2013 Jan; 27 Suppl 1():3-12. PubMed ID: 23990277
    [TBL] [Abstract][Full Text] [Related]  

  • 47. IL-17 for therapy.
    Kurschus FC; Moos S
    J Dermatol Sci; 2017 Sep; 87(3):221-227. PubMed ID: 28633806
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Specific targeting of interleukin-23p19 as effective treatment for psoriasis.
    Levin AA; Gottlieb AB
    J Am Acad Dermatol; 2014 Mar; 70(3):555-61. PubMed ID: 24373779
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interleukin-17-producing γδ T (γδ17) cells in inflammatory diseases.
    Akitsu A; Iwakura Y
    Immunology; 2018 Dec; 155(4):418-426. PubMed ID: 30133701
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bone remodeling in psoriasis and psoriatic arthritis: an update.
    Paine A; Ritchlin C
    Curr Opin Rheumatol; 2016 Jan; 28(1):66-75. PubMed ID: 26555451
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Involvement of IL-17F via the induction of IL-6 in psoriasis.
    Fujishima S; Watanabe H; Kawaguchi M; Suzuki T; Matsukura S; Homma T; Howell BG; Hizawa N; Mitsuya T; Huang SK; Iijima M
    Arch Dermatol Res; 2010 Sep; 302(7):499-505. PubMed ID: 20148256
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond.
    Brembilla NC; Senra L; Boehncke WH
    Front Immunol; 2018; 9():1682. PubMed ID: 30127781
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis.
    Singh TP; Schön MP; Wallbrecht K; Gruber-Wackernagel A; Wang XJ; Wolf P
    PLoS One; 2013; 8(1):e51752. PubMed ID: 23335955
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Secukinumab (AIN-457) for the treatment of Psoriasis.
    Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
    Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Autoimmune inflammation from the Th17 perspective.
    Furuzawa-Carballeda J; Vargas-Rojas MI; Cabral AR
    Autoimmun Rev; 2007 Jan; 6(3):169-75. PubMed ID: 17289553
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Th17 cells and IL-17 a--focus on immunopathogenesis and immunotherapeutics.
    van den Berg WB; McInnes IB
    Semin Arthritis Rheum; 2013 Oct; 43(2):158-70. PubMed ID: 24157091
    [TBL] [Abstract][Full Text] [Related]  

  • 57. IL-37 Alleviates Rheumatoid Arthritis by Suppressing IL-17 and IL-17-Triggering Cytokine Production and Limiting Th17 Cell Proliferation.
    Ye L; Jiang B; Deng J; Du J; Xiong W; Guan Y; Wen Z; Huang K; Huang Z
    J Immunol; 2015 Jun; 194(11):5110-9. PubMed ID: 25917106
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prospective new biologic therapies for psoriasis and psoriatic arthritis.
    Mortel MR; Emer J
    J Drugs Dermatol; 2010 Aug; 9(8):947-58. PubMed ID: 20684145
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.
    Tillack C; Ehmann LM; Friedrich M; Laubender RP; Papay P; Vogelsang H; Stallhofer J; Beigel F; Bedynek A; Wetzke M; Maier H; Koburger M; Wagner J; Glas J; Diegelmann J; Koglin S; Dombrowski Y; Schauber J; Wollenberg A; Brand S
    Gut; 2014 Apr; 63(4):567-77. PubMed ID: 23468464
    [TBL] [Abstract][Full Text] [Related]  

  • 60. IL-12-and IL-23 in health and disease.
    Croxford AL; Kulig P; Becher B
    Cytokine Growth Factor Rev; 2014 Aug; 25(4):415-21. PubMed ID: 25130295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 65.